AUTHORS
Shicong Zhu, PhD, Marlena Langdon2, Anisha Jackson3, Quynn Hotan4, Kathryn Ye5, A Josephine Thrasher6, Megan Saari7, Osheiza Abdulmalik, DVM8, Junwei Shi, PhD9, Elizabeth Traxler, MD,PhD10
AFFILIATIONS
1 University of Pennsylvania, Philadelphia, United States
2 University of Pennsylvania, Philadelphia, United States
3 University of Pennsylvania, Philadelphia, United States
4 University of Pennsylvania, Philadelphia, United States
5 University of Pennsylvania, Philadelphia, United States
6 University of Pennsylvania, Philadelphia, United States
7 University of Pennsylvania, Philadelphia, United States
8 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
9 University of Pennsylvania, Philadelphia, United States
10 University of Pennsylvania, Philadelphia, United States
ABSTRACT
Reactivation of the fetal globin genes (HBG1/2) can functionally compensate for abnormal adult β-globin in β-hemoglobinopathies. Several repressors of HBG expression including BCL11A, LRF, and NFIA/X were identified by human genetics studies and genetic screening. In a multi-tiered approach, we interrogated novel HBG regulators in immortalized HUDEP2 cells using genome-scale and custom CRISPR screens. Our data revealed that five of the top candidate genes were subunits of the SAGA (Spt-Ada-Gcn5 acetyltransferase) transcriptional co-activator complex. SAGA is comprised of 20 proteins that are organized into functional modules to promote gene transcription via histone acetylation and deubiquitination. CRISPR sgRNAs towards four subunits of the core module (TAF5L, TAF6L, SUPT7L, and TADA1) and one subunit of the histone acetyltransferase module (TADA3) were enriched in high-HBG expressing cells. Furthermore, SAGA-targeting sgRNAs did not impact cellular fitness, suggesting that selective SAGA inhibition may be promising therapeutically. Comparing the effects across all known SAGA complex members, SAGA core subunits TAF5L and TAF6L demonstrated the strongest effects on HBG expression. Thus, we focused subsequent studies on TAF5L and TAF6L.
Depleting TAF5L and TAF6L in HUDEP2 cells and in primary human CD34+ derived erythroblasts increased HBG mRNA and fetal hemoglobin protein expression by flow cytometry and high performance liquid chromatography, validating the screening results. We next investigated the mechanisms of SAGA-mediated HBG repression. Profiling TAF5L and TAF6L genome-wide in HUDEP2 cells demonstrated predominant occupancy at gene promoters. Notably, both factors occupy BCL11A and LRF gene promoters. We then conducted RNA polymerase II chromatin occupancy to evaluate how transcriptional machinery recruitment changes upon TAF5L or TAF6L-depletion. Pol II occupancy decreased after SAGA depletion, prominently at BCL11A, LRF, and other SAGA-bound genes. Accordingly, BCL11A expression was reduced in TAF5L-deficient HUDEP2 and primary human erythroblasts. To further examine the direct mechanisms of SAGA, we performed two genetic rescue experiments with TAF5L and BCL11A. TAF5L overexpression in TAF5L-depleted cells completely restored BCL11A and HBG expression. Moreover, BCL11A overexpression in TAF5L or TAF6L knockdown cells rescued HBG expression levels, thereby establishing BCL11A is a critical SAGA target. Altogether, genome-wide CRISPR screening identified SAGA’s core subunits TAF5L and TAF6L as novel fetal globin regulators. Thus, despite its wide expression and precedent as a general transcriptional coactivator, SAGA can exert locus specific functions in an erythroid context.
DISCLOSURES
Shicong Zhu, PhD: No relevant conflicts of interest to declare.